膜杰作
Star Staining
分子别名（Synonym）
IL-18,Interleukin-18,IL18,IL-1 gamma,IGIF,IL1F4,IL-1F4
表达区间及表达系统（Source）
Mouse IL-18 Protein, His Tag (IL8-M51H3) is expressed from E. coli cells. It contains AA Asn 36 - Ser 192 (Accession # P70380).
Predicted N-terminus: Asn
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 20.0 kDa. The protein migrates as 20-22 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>90% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Mouse IL-18 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
活性（Bioactivity）-ELISA
Immobilized Recombinant Mouse IL-18 BPd Fc Chimera Protein, CF at 5 μg/mL (100 μL/well) can bind Mouse IL-18 Protein, His Tag (Cat. No. IL8-M51H3) with a linear range of 0.2-10 ng/mL (QC tested).
Protocol
背景（Background）
Interleukin-18 (IL-18) is a potent proinflammatory cytokine that induces interferon-gamma (IFN-gamma) production from Th1 cells, NK cells and activated macrophages, particularly in the presence of IL-12. IL-18 also functions in developmental regulation of T-lymphocyte helper type I cells and in Fas-mediated cytotoxicity. Suppression of IL-18 activity is being investigated for treatment of chronic inflammatory diseases such as Crohn's disease and rheumatoid arthritis. It acts by inducing heterodimerization of the two subunits of its receptor, IL-18RAlpha and IL-18RBeta shows structural similarity to IL-1.
